Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04614103 · ClinicalTrials.gov registry record · Phase 2
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
A Phase 2 study of Metastatic Non Small Cell Lung Cancer, sponsored by Iovance Biotherapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 170
- Enrollment target
- 20
- Study locations
NCT04614103: Recruiting Phase 2 study of Metastatic Non Small Cell Lung Cancer, sponsored by Iovance Biotherapeutics.
NCT04614103 is a Phase 2 study of Metastatic Non Small Cell Lung Cancer that is actively recruiting participants, run by Iovance Biotherapeutics. The registered enrollment target is 170 participants, below the 377-participant average among 31 other Metastatic Non Small Cell Lung Cancer trials with a reported enrollment target (55% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04614103, a Phase 2 study of Metastatic Non Small Cell Lung Cancer, is actively recruiting participants, sponsored by Iovance Biotherapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 170 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung cancer
Primary Outcome
To evaluate the efficacy of LN-145 as determined by objective response rate (ORR) in patients with metastatic NSCLC using the Response Evaluation Criteria in Solid Tumors (RECIST v1.1), as assessed by central review for Cohorts 1 and 2 and by the investigator for Cohorts 3, 4 and the Retreatment Cohort
Conditions Studied
Interventions
- BIOLOGICAL LN-145
Study Locations (20)
Florida
- University of Florida Health Cancer Center - Gainesville
- Sylvester Comprehensive Cancer Center - Miami
- AdventHealth Cancer Institute - Orlando
- H Lee Moffitt Cancer Center and Research Institute - Tampa
California
- City of Hope - Duarte
- UC San Diego Moores Cancer Center - La Jolla
- University of Southern California - Los Angeles
Illinois
- Rush University Medical Center - Chicago
- University of Illinois Hospital & Health Sciences System - Chicago
- Advocate Aurora Health - Park Ridge
Kentucky
- University of Kentucky-Markey Cancer Center - Lexington
- University of Louisville - Louisville
Michigan
- Karmanos Cancer Institute - Detroit
- Henry Ford Health System - Detroit
Delaware
- Christiana Care Health System - Newark
Georgia
- Augusta University - Augusta
Maryland
- University of Maryland - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2021-05-07 |
| Est. Completion | 2031-12 |
| Phase | Phase 2 |
What NCT04614103 shows while recruiting
NCT04614103 is an interventional study that assigns participants to a tested intervention. The registered 170 participants enrollment target is mid-sized for trials with a published cap, below the 377-participant average among 31 other Metastatic Non Small Cell Lung Cancer trials with a reported enrollment target (55% lower).
The record links to 1 condition, with Metastatic Non Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which LN-145 is the first listed.
NCT04614103 names 20 study sites across 11 states, led by Florida, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT04614103 about?
NCT04614103 is a clinical study titled "Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer". This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung cancer
What is the current status of trial NCT04614103?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 170 participants. The study started on 2021-05-07. Estimated completion is 2031-12.
What conditions does trial NCT04614103 study?
This clinical trial studies the following conditions: Metastatic Non Small Cell Lung Cancer.
What interventions are being tested in trial NCT04614103?
The interventions under investigation include: LN-145 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04614103?
This trial is sponsored by Iovance Biotherapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04614103 being conducted?
This trial has 20 study locations across California, Delaware, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Non Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04614103's enrollment target sits among peer trials
170 18th of 31 higher than 14 of 31 other Metastatic Non Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Non Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
RECRUITING · Phase 2
-
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
RECRUITING · Phase 2
-
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
ACTIVE NOT RECRUITING · Phase 2
-
Plasma-Adapted First-Line Pembro In NSCLC
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
- NCT04166409 · 170 participants · Phase 3
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI